0001437749-22-006190.txt : 20220314
0001437749-22-006190.hdr.sgml : 20220314
20220314194306
ACCESSION NUMBER: 0001437749-22-006190
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220314
DATE AS OF CHANGE: 20220314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUNT DOUGLAS M
CENTRAL INDEX KEY: 0001727172
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 22738353
MAIL ADDRESS:
STREET 1: C/O PUMA BIOTECHNOLOGY,INC.
STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-03-03
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001727172
HUNT DOUGLAS M
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
See Remarks
Common Stock
2022-03-03
4
A
0
22647
0
A
82751
D
Stock Option (Right to Buy)
2.33
2022-03-03
4
A
0
32353
0
A
2032-03-02
Common Stock
32353
32353
D
Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024.
Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024.
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
/s/ Douglas M. Hunt
2022-03-14